# ERICH1

## Overview
ERICH1, or glutamate rich 1, is a gene that encodes a protein of the same name, which is characterized by its high glutamate content. The protein is not classified into a specific category such as kinase or receptor, but it plays a significant role in various biological processes and disease mechanisms. ERICH1 is involved in transcriptional regulation and has been linked to immune system modulation, particularly in the context of autoimmune diseases like myasthenia gravis (Zhang2023Transcriptional). Additionally, ERICH1 is associated with placental development and disorders, as well as colorectal cancer, where its methylation status may serve as a biomarker for certain cancer types (Apicella2023PanGenomic; GallardoGómez2022Serum). The gene's diverse roles in health and disease underscore its potential as a target for further research and therapeutic intervention.

## Clinical Significance
ERICH1 (glutamate rich 1) has been implicated in several diseases and conditions through alterations in its expression or interactions. In myasthenia gravis (MG), ERICH1 is characterized by significantly low expression levels, which may influence the immune microenvironment and affect immune cell infiltration and immune-related gene expression (Zhang2023Transcriptional). The gene's expression is also associated with placental biology, where it is identified as an eGene with significant associations to conditions like preeclampsia and intrauterine growth restriction, although the specific clinical implications in these contexts are not fully detailed (Apicella2023PanGenomic).

In colorectal cancer (CRC), particularly in the serrated pathway, ERICH1 is involved in differential methylation profiles. The methylation status of ERICH1, along with other genes, shows potential as a biomarker for detecting high-risk serrated lesions and serrated adenocarcinoma, with high sensitivity and specificity (GallardoGómez2022Serum). These findings suggest that ERICH1's expression and methylation patterns could serve as important indicators in the diagnosis and understanding of various pathological conditions.


## References


[1. (Apicella2023PanGenomic) Clara Apicella, Camino S. M. Ruano, Basky Thilaganathan, Asma Khalil, Veronica Giorgione, Géraldine Gascoin, Louis Marcellin, Cassandra Gaspar, Sébastien Jacques, Colin E. Murdoch, Francisco Miralles, Céline Méhats, and Daniel Vaiman. Pan-genomic regulation of gene expression in normal and pathological human placentas. Cells, 12(4):578, February 2023. URL: http://dx.doi.org/10.3390/cells12040578, doi:10.3390/cells12040578. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12040578)

2. (GallardoGómez2022Serum) Serum DNA methylome of the colorectal cancer serrated pathway. This article has 0 citations.

[3. (Zhang2023Transcriptional) Demin Zhang, Liqin Luo, Feng Lu, Bo Li, and Xiaoyun Lai. Transcriptional landscape of myasthenia gravis revealed by weighted gene coexpression network analysis. Frontiers in Genetics, March 2023. URL: http://dx.doi.org/10.3389/fgene.2023.1106359, doi:10.3389/fgene.2023.1106359. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2023.1106359)